IndicationsLenalidomide is a thalidomide analogue indicated for the treatment of adult patients with the following conditions:
- Multiple myeloma (MM), in combination with dexamethasone.
- Multiple myeloma (MM), as maintenance therapy following autologous hematopoietic stem cell transplantation (auto-HSCT).
- Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with deletion 5q abnormality, with or without additional cytogenetic abnormalities.
- Mantle cell lymphoma (MCL) that has relapsed or progressed after at least two prior therapies, including one with bortezomib.
- Previously treated follicular lymphoma (FL), in combination with a rituximab product.
- Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.
Use Limitation:
Lenalidomide is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.Dosage and Administration
- MM in combination therapy: 25 mg orally once daily on Days 1–21 of repeated 28-day cycles.
- MM maintenance therapy following auto-HSCT: 10 mg orally once daily on Days 1–28 of repeated 28-day cycles.
- MDS: 10 mg orally once daily.
- MCL: 25 mg orally once daily on Days 1–21 of repeated 28-day cycles.
- FL or MZL: 20 mg orally once daily on Days 1–21 of repeated 28-day cycles, for up to 12 cycles.
- Renal Impairment: Adjust the starting dose based on creatinine clearance.
- For dosing of concomitant therapies, refer to the full prescribing information.
Reviews
There are no reviews yet.